New immunosuppressive agents and risk for invasive fungal infections

Georg Maschmeyer, Thomas F Patterson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

Original languageEnglish (US)
Pages (from-to)435-438
Number of pages4
JournalCurrent Infectious Disease Reports
Volume11
Issue number6
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Mycoses
Interleukin-2 Receptors
Hematopoietic Stem Cells
Autoimmune Diseases
Anti-Idiotypic Antibodies
Fungi
Invasive Fungal Infections
Transplants
Mortality
Antibodies
Incidence
Infection
Neoplasms
alemtuzumab

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

New immunosuppressive agents and risk for invasive fungal infections. / Maschmeyer, Georg; Patterson, Thomas F.

In: Current Infectious Disease Reports, Vol. 11, No. 6, 11.2009, p. 435-438.

Research output: Contribution to journalArticle

@article{ff922f835367442d87cb3627a39c487d,
title = "New immunosuppressive agents and risk for invasive fungal infections",
abstract = "Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.",
author = "Georg Maschmeyer and Patterson, {Thomas F}",
year = "2009",
month = "11",
doi = "10.1007/s11908-009-0063-x",
language = "English (US)",
volume = "11",
pages = "435--438",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - New immunosuppressive agents and risk for invasive fungal infections

AU - Maschmeyer, Georg

AU - Patterson, Thomas F

PY - 2009/11

Y1 - 2009/11

N2 - Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

AB - Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

UR - http://www.scopus.com/inward/record.url?scp=70449492955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449492955&partnerID=8YFLogxK

U2 - 10.1007/s11908-009-0063-x

DO - 10.1007/s11908-009-0063-x

M3 - Article

C2 - 19857382

AN - SCOPUS:70449492955

VL - 11

SP - 435

EP - 438

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 6

ER -